Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.

Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.

View in: PubMed

subject areas

Adult
Aged
Clinical Trials, Phase III as Topic
Double-Blind Method
Female
Glucagon-Like Peptides
Humans
Hypoglycemic Agents
Liver
Liver Cirrhosis
Male
Middle Aged
Multicenter Studies as Topic
Non-alcoholic Fatty Liver Disease
Randomized Controlled Trials as Topic
Treatment Outcome

authors with profiles

Mary Rinella